16.01.2013 • News

Lonza, BaroFold Announce Technology Evaluation Agreement for PreEMT

Lonza, a leader in biological development and BaroFold, an protein technology developer, announced today a non-exclusive technology and license agreement whereby Lonza will evaluate BaroFold's PreEMT high pressure refolding technology for use in biological development refolding processes. Lonza's evaluation will focus on refolding difficult to express microbial products expressed as inclusion bodies. The PreEMT unit will be installed for evaluation at Lonza's microbial development and manufacturing plant in Visp, Switzerland.

The agreement includes an option for Lonza to extend the platform evaluation to GMP production analysis.

 

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

Virtual Event

Outsourced Biomanufacturing
Strategic Outsourcing in Biopharmaceuticals

Outsourced Biomanufacturing

April 22, 2026 | Join biopharma professionals, CDMO leaders, and supply chain innovators for a virtual event exploring the future of outsourced biomanufacturing.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.